Vericel Corp Ord (VCEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vericel Corp Ord (VCEL) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.01 Million) by net assets ($354.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vericel Corp Ord (VCEL) balance sheet quality index to measure how much of total assets are equity-financed.
Vericel Corp Ord - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vericel Corp Ord earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Vericel Corp Ord Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vericel Corp Ord ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Believe SAS
PA:BLV
|
0.049x |
|
NEXA RESOURCES S.A. DL 1
F:NE0
|
0.218x |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
|
BBMG Corp Class A
SHG:601992
|
-0.025x |
|
A.F.P. Provida
SN:PROVIDA
|
0.022x |
|
Hap Seng Consolidated Bhd
KLSE:3034
|
0.034x |
|
DCM Shriram Limited
NSE:DCMSHRIRAM
|
0.210x |
|
Cloetta AB (publ)
ST:CLA-B
|
0.074x |
Annual Cash Flow Conversion Efficiency for Vericel Corp Ord (1995–2025)
The table below shows the annual cash flow conversion efficiency of Vericel Corp Ord from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vericel Corp Ord.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.64 Million | $51.91 Million | 0.146x | -26.52% |
| 2024-12-31 | $291.97 Million | $58.16 Million | 0.199x | +27.47% |
| 2023-12-31 | $225.95 Million | $35.31 Million | 0.156x | +69.89% |
| 2022-12-31 | $192.27 Million | $17.69 Million | 0.092x | -46.00% |
| 2021-12-31 | $170.46 Million | $29.04 Million | 0.170x | +30.17% |
| 2020-12-31 | $134.26 Million | $17.57 Million | 0.131x | +302.42% |
| 2019-12-31 | $111.09 Million | $-7.18 Million | -0.065x | -1504.40% |
| 2018-12-31 | $102.23 Million | $-412.00K | -0.004x | +99.31% |
| 2017-12-31 | $22.54 Million | $-13.18 Million | -0.585x | +27.35% |
| 2016-12-31 | $24.71 Million | $-19.89 Million | -0.805x | -33.49% |
| 2015-12-31 | $22.13 Million | $-13.35 Million | -0.603x | +15.41% |
| 2014-12-31 | $35.64 Million | $-25.41 Million | -0.713x | +86.08% |
| 2013-12-31 | $3.89 Million | $-19.94 Million | -5.121x | -64.90% |
| 2012-12-31 | $9.51 Million | $-29.55 Million | -3.106x | -264.48% |
| 2011-12-31 | $-12.97 Million | $-24.49 Million | 1.888x | +136.58% |
| 2010-12-31 | $2.92 Million | $-15.09 Million | -5.163x | -546.36% |
| 2009-12-31 | $17.28 Million | $-13.80 Million | -0.799x | +4.56% |
| 2008-12-31 | $23.33 Million | $-19.53 Million | -0.837x | -59.46% |
| 2007-12-31 | $28.25 Million | $-14.83 Million | -0.525x | -64.38% |
| 2006-12-31 | $42.34 Million | $-13.52 Million | -0.319x | +4.70% |
| 2005-12-31 | $33.03 Million | $-11.06 Million | -0.335x | +38.07% |
| 2004-12-31 | $17.61 Million | $-9.53 Million | -0.541x | +30.35% |
| 2003-12-31 | $11.57 Million | $-8.99 Million | -0.777x | +4.10% |
| 2002-12-31 | $10.80 Million | $-8.75 Million | -0.810x | -38.68% |
| 2001-12-31 | $10.89 Million | $-6.36 Million | -0.584x | -5.60% |
| 2000-12-31 | $12.44 Million | $-6.88 Million | -0.553x | +57.97% |
| 1999-12-31 | $8.51 Million | $-11.20 Million | -1.316x | +8.75% |
| 1998-12-31 | $10.85 Million | $-15.64 Million | -1.442x | -103.97% |
| 1997-12-31 | $18.81 Million | $-13.30 Million | -0.707x | +11.77% |
| 1996-12-31 | $16.60 Million | $-13.30 Million | -0.801x | +57.74% |
| 1995-12-31 | $4.80 Million | $-9.10 Million | -1.896x | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more